全文获取类型
收费全文 | 10105929篇 |
免费 | 646774篇 |
国内免费 | 161365篇 |
专业分类
耳鼻咽喉 | 130928篇 |
儿科学 | 282388篇 |
妇产科学 | 231945篇 |
基础医学 | 1255262篇 |
口腔科学 | 264637篇 |
临床医学 | 1024792篇 |
内科学 | 1696346篇 |
皮肤病学 | 203849篇 |
神经病学 | 730650篇 |
特种医学 | 377963篇 |
外国民族医学 | 1735篇 |
外科学 | 1331243篇 |
综合类 | 715195篇 |
现状与发展 | 513篇 |
一般理论 | 3727篇 |
预防医学 | 805022篇 |
眼科学 | 230783篇 |
药学 | 866528篇 |
2790篇 | |
中国医学 | 213968篇 |
肿瘤学 | 543804篇 |
出版年
2022年 | 127830篇 |
2021年 | 199535篇 |
2020年 | 141926篇 |
2019年 | 145463篇 |
2018年 | 177616篇 |
2017年 | 158343篇 |
2016年 | 152505篇 |
2015年 | 190655篇 |
2014年 | 278533篇 |
2013年 | 369822篇 |
2012年 | 522583篇 |
2011年 | 567328篇 |
2010年 | 384715篇 |
2009年 | 345777篇 |
2008年 | 482980篇 |
2007年 | 503536篇 |
2006年 | 481495篇 |
2005年 | 445241篇 |
2004年 | 389162篇 |
2003年 | 360869篇 |
2002年 | 332375篇 |
2001年 | 312740篇 |
2000年 | 311542篇 |
1999年 | 267265篇 |
1998年 | 111750篇 |
1997年 | 98483篇 |
1996年 | 92295篇 |
1995年 | 84300篇 |
1994年 | 76440篇 |
1993年 | 65678篇 |
1992年 | 183695篇 |
1991年 | 177680篇 |
1990年 | 172306篇 |
1989年 | 167247篇 |
1988年 | 154560篇 |
1987年 | 150349篇 |
1986年 | 143236篇 |
1985年 | 136433篇 |
1984年 | 103875篇 |
1983年 | 89131篇 |
1982年 | 56765篇 |
1979年 | 93142篇 |
1978年 | 66795篇 |
1977年 | 57604篇 |
1976年 | 53404篇 |
1975年 | 58439篇 |
1974年 | 67420篇 |
1973年 | 64329篇 |
1972年 | 59456篇 |
1971年 | 55074篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
122.
123.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy 相似文献
124.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
125.
126.
目的 运用CT区分脾脏血管性病变与淋巴瘤。方法 回顾性分析20例经手术、穿刺病理学检查证实的脾脏病变的发病年龄、性别、脾脏指数、病变大小、数目、有无液化、钙化、强化幅度、强化方式等特征,并进行统计学分析。结果 20例脾脏病变中,11例血管性病变(6例海绵状血管瘤,3例窦岸细胞血管瘤,2例硬化性血管瘤样结节性转化),9例淋巴瘤;两组间发病年龄、病变大小、数目、有无液化、钙化等差异无统计学意义;两组间脾脏指数、动脉期强化幅度差异具有统计学意义(P<0.05)。5例海绵状血管瘤呈不均匀性强化,1例呈渐进性填充式强化,2例窦岸细胞血管瘤呈“雀斑征”,1例硬化性血管瘤样结节性转化呈“辐轮征”;9例淋巴瘤实质部分均呈均匀、轻中度强化。结论 脾脏血管性病变与淋巴瘤CT表现不同,CT有助于明确诊断。 相似文献
127.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
128.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
129.
130.
Background:We aim to evaluate the efficiency of Raman spectroscopy (RS) in diagnosing suspected patients with intrahepatic cholangiocarcinoma (ICC), manifested by diagnostic sensitivity, specificity, and accuracy.Methods:We will research widely the articles concerning the use of RS in ICC through authenticated database including PubMed/Medline, EMBASE, Web of Science, Ovid, Web of Knowledge, Cochrane Library, and CNKI between January 2012 and November 2020, retrieving at least 1500 spectra with strict criteria. This study will be carried out in accordance to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We are going to summarize the test performance using random effects models.Results:Based on the pooled sensitivity, specificity, and diagnostic accuracy, we intend to provide the relative diagnostic efficiency in ICC through RS.Conclusion:Through this systematic review and meta-analysis, we intend to provide the pooled sensitivity, specificity and diagnostic accuracy of RS in the diagnosis of suspected ICC. Other parameters like positive likelihood ratios (LR), negative LR, diagnostic odds ratio (DOR), and area under curve (AUC) of the summary receiver operating characteristics (SROC) curve will also be calculated and related figures will be drawn to help illustrate the efficacy of RS in the diagnosis of ICC. 相似文献